Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DUTJ12
|
|||
| Drug Name |
ICP-022
|
|||
| Synonyms |
Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 3 | [1] | |
| Small lymphocytic lymphoma [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 3 | [1] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [2] | ||
| Company |
InnoCare Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H25N3O3
|
|||
| Canonical SMILES |
C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
|
|||
| InChI |
1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
|
|||
| InChIKey |
MZPVEMOYADUARK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1655504-04-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04578613) ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04438005) A Study of ICP-022 in Patients With R/R DLBCL (DLBCL). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of InnoCare Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.